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This is one of a series of occasional articles on therapeutics for common
or serious conditions, covering new drugs and old drugs with important
new indications or concerns. The series advisers are Robin Ferner,
honorary professor of clinical pharmacology, University of Birmingham
and BirminghamCity Hospital, and Philip Routledge, professor of clinical
pharmacology, Cardiff University. To suggest a topic for this series,
please email us at practice@bmj.com.
A 39 year old woman started injecting heroin when she was 18
but soon found she could not control her drug intake or her life
in general. At age 30, she sought help and did well with
methadone treatment, taking no illicit drugs for three years.
However, she then relapsed to heroin use and spent a year in
prison, where she continued to inject heroin. After being
released, she went to a residential rehabilitation centre.
Subsequently in the community her general practitioner started
her on buprenorphine. Her life became more stable. She did
well with buprenorphine treatment for a few years but restarted
injecting heroin after stopping buprenorphine. She restarted
buprenorphine and now takes no non-prescribed medication.
She works as a waitress and lives with her non-drug using
partner.
What is opioid dependence?
This article is intended for practitioners who occasionally
manage patients with opioid dependence. Methadone, a mu
opioid agonist, and buprenorphine, a partial agonist, are the
main drug treatments for dependence on opioids (which include
heroin, morphine, and oxycodone, as well as the other
pharmaceutical opioids1 2) for detoxification, maintenance, and
ultimately abstinence. Treatment with maintenance goals is
referred to as opioid substitution treatment or opioid agonist
pharmacotherapy.3 Such treatment is reserved for patients with
clearly established opioid dependence and prolonged daily
opioid use (by either smoking or injecting). In some countries
the combination of buprenorphine and naloxone is preferred
(and is now becoming available as a film taken sublingually).
Prescription heroin, known in the United Kingdom as heroin
assisted treatment or injectable opiate treatment, is used in some
countries but is not discussed in this article.4-6Naltrexone blocks
the effects of heroin on the mu receptor,2 but oral naltrexone
treatment has had low adherence and high discontinuity rates.7 8
Use of naltrexone in the form of implants and extended release
injection is currently in the research and development phase9
and is outside the scope of this paper.
How well do methadone and
buprenorphine work?
More than 30 randomised controlled trials report moderately
strong evidence of efficacy as measured by reduction in
non-prescribed opioid use, reduction in mortality, and retention
in treatment.3 10-13 A Cochrane review found that retention in
treatment was lower for buprenorphine than for methadone
when flexible doses were used (relative risk 0.85; 95%
confidence interval 0.73 to 0.98).11 This translates to a number
needed to treat of 9.62, indicating that for every nine people
treated with methadone one additional person will be retained
in treatment than would be the case with buprenorphine. Despite
the breadth of published evidence (summarised in the table⇓),
opioid substitution treatment remains controversial, with some
strongly polarised views on the priority of outcomes ranging
from stable maintenance to stable abstinence from all drugs.
Data on mortality from randomised controlled trials is weak
because of the small size of the studies, but larger scale cohort
studies report a significant reduction in mortality for methadone
maintenance compared with no treatment (relative risk 0.17;
0.05 to 0.63).3 A wide range of clinical guidelines including
those from the World Health Organization,3 National Institute
for Health and Clinical Excellence (NICE)14 and more than 20
multilingual national guidelines,1 15 support the use of methadone
and buprenorphine. Although treatment often includes
psychosocial assistance (as in the case scenario above), the
nature, extent, and benefits of adjuvant psychosocial assistance
is uncertain.3 16Nevertheless, psychosocial assistance is generally
demanded as a necessary component of the overall treatment
programme and considered an indicator of quality. When
cessation of medication is unplanned, most individuals return
to heroin use and crime.17
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How safe are methadone and
buprenorphine?
A recent analysis of data from the UKGeneral Practice Research
Database calculated standardised mortality ratios of 5.3 (95%
confidence interval 4.0 to 6.8) for patients “on treatment” (taking
opiate substitution treatment) and 10.9 (9.0 to 13.1) for patients
“off treatment” (not taking it).18 Other studies have also found
high rates of deaths from overdose after cessation of opiate
substitution treatment, and significantly lower annual death
rates for those in continuous opiate substitution treatment (1.6%)
compared with death rates in the year after patients stopped
treatment (8.2%).17 This substantial difference in mortality
risk3 17-19 makes both methadone and buprenorphine important
agents for reducing mortality in a treatment population.
Methadone
The first two weeks after methadone is started has been reported
as being associated with a greater risk of death (crude mortality
rate 1.7 per 100 person years compared with 1.3 per 100 person
years for those off treatment),18 but once patients are stabilised
on methadone the mortality risk drops significantly (to 1.32 per
100 person years in weeks 3 and 4 of treatment, and to 0.61 per
100 person years for the rest of time on treatment).1 18 20
A dose related prolongation of the QT interval and sleep apnoea
is reported with methadone, but cardiac events are infrequently
reported.21 Individuals with a history of cardiac disease and
those taking very high doses of methadone should have
electrocardiography.
Buprenorphine
Buprenorphine is less of a depressant than methadone and is
thought to cause a lower mortality risk from overdose at the
start of treatment, and fewer QT interval changes, but
insufficient data are available for quantifying the difference.
What are the precautions?
Starting treatment
Cautious dose initiation withmethadone is essential. Supervision
of dispensed medication is needed, together with regular
monitoring and review with appropriate adjustment of dosage.1
If the patient has received treatment recently elsewhere, obtain
full information about that treatment from the previous
prescribing doctor and/or dispensing pharmacist and check that
the patient is not currently receivingmedication from elsewhere.1
The half life of a single first dose of methadone is 12-18 hours,
with a mean of 15 hours. With ongoing dosing, the half life of
methadone is extended to 13-47 hours with a mean of 24 hours.
This prolonged half life contributes to the fact that blood
methadone concentrations continue to rise during the first week
of daily dosing and fall relatively slowly between doses.
Methadone reaches steady state in the body (where drug
elimination equals the rate of drug administration) after a period
equivalent to 4-5 half lives or 3-10 days. Clinicians should
explain clearly that it takes time to complete induction on to
methadone and that patients will experience increasing effects
from methadone over the first few days of treatment even if the
dose is not increased.
Contraindications and use of other drugs
There are no absolute contraindications to methadone or
buprenorphine. However, all patients starting on methadone
and buprenorphine must be informed of the risk of toxicity and
overdose. The risk is highest in the initial period of treatment
as stable blood concentrations of methadone are achieved,
particularly if heroin or other sedating drugs are used on top of
the prescribed medication.
Use of hypnosedative medication with either buprenorphine or
methadone is associated with increased risk of overdose and
death.1 When patients are reporting heavy use of alcohol and
benzodiazepines and other sedativemedication, exercise extreme
caution in the early induction and subsequent maintenance
phase. In addition, it is essential that the medication is safely
stored to avoid children taking it. Supervised dispensing is an
important safety strategy, to improve treatment adherence and
reduce risk of overdose. Medication supervision will enable
monitoring and liaison with the dispensing pharmacist and is
strongly encouraged, at least in the early phase of treatment.
Avoid coprescribing of benzodiazepines and tricyclic
antidepressants as far as possible. Antiretroviral treatments may
interact with methadone, less so with buprenorphine; monitoring
is needed, with appropriate dose adjustment.
Severe liver and renal disease
Severe liver and renal disease can result in dose accumulation
resulting from slow metabolism and delayed elimination.
Consider dose reduction or complete withdrawal when the
patient is at risk of hepatic encephalopathy. Monitor liver
function enzymes for patients prescribed high doses of
buprenorphine. Buprenorphine is contraindicated in the presence
of severe liver disease.
Pregnancy and breast feeding
Methadone is safe and effective in terms of consistently better
obstetric and perinatal outcomes22 23 compared with pregnancies
in opioid dependent women not receiving opioid substitution
treatment. Further studies of buprenorphine in pregnancy are
needed, but studies to date indicate its potential usefulness.24
Opioid substitution treatment can be associated with neonatal
abstinence syndrome, but this can be readily managed with
withdrawal mangement and supportive care. If required or
indicated, medications such as methadone, tincture of opium,
morphine, or diazepam can be titrated to withdrawal symptoms.
Side effects
The most critical side effect is overdose toxicity (fatal and
non-fatal), which seems to be a higher risk with methadone than
with buprenorphine.1 2 Other side effects of opiates are
constipation, sweating, pruritis, loss of libido, and impotence.
Patients also complain of severe difficulty in withdrawing from
methadone and argue that it results in longer dependence on
opioids for them. Clinicians and users state that it is easier to
withdraw from buprenorphine, but no robust evidence exists to
support this belief.
How cost effective are methadone and
buprenorphine?
TheNICE andWHOguidelines both considered the comparative
cost effectiveness of methadone and buprenorphine.3 13
Methadone costs less and was more cost effective than
buprenorphine,3 but when other factors (such as patient choice,
treatment retention, and the comparatively greater need for
supervised dispensing with methadone) were taken into account,
NICE concluded that there was a good case for clinicians and
patients having access to both medications and for individual
clinical considerations to determine which drug to prescribe.13
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e2823 doi: 10.1136/bmj.e2823 (Published 15 May 2012) Page 2 of 5
PRACTICE
Overall, both methadone and buprenorphine are highly cost
effective when compared to no treatment. Treatment confers a
£5 saving for every £1 spent—that is, savings in costs of
criminal justice and health and social care (box 1).13
How are methadone and buprenorphine
taken and monitored?
Methadone is taken orally, buprenorphine sublingually. In most
settings the initial period of medication is under the supervision
and observation of a pharmacy or clinic, where instalment
prescriptions are written to enable daily or regular supervised
dispensing of medication. Methadone is taken once daily. Most
patients take buprenorphine daily, but some take it every other
day or very occasionally three times a week.Methadone requires
low dose induction, with a maximum initial dose of 30-40 mg
(but note that 30 mg is a potentially fatal dose in a non-tolerant
individual); maintenance doses range from 60 mg to 120 mg,
built up over time. Buprenorphine doses can be increased at a
faster rate but may precipitate opioid withdrawal if heroin has
been recently consumed. Box 2 provides practical guidance to
doctors for prescribing these agents, and box 3 outlines tips for
patients.
Supervised urine collection and analysis can show if the patient
is using non-prescribed drugs but this adds to costs. The
evidence for cost effectiveness of urine testing is weak.
How do methadone and buprenorphine
comparewith other drugs and each other?
Compared with buprenorphine, methadone is associated with
considerable stigma but is less expensive, achieves higher rates
of retention, and has been used more extensively and evaluated
more frequently.3 10-12 19 The increased risk of death when starting
methadone can be reduced by adherence to induction guidelines.
Some people find both methadone and buprenorphine
unacceptable, and use of dihydrocodeine25 has been tried off
licence with reasonable success. Studies of slow release oral
morphine have also reported positive outcomes.26Heroin assisted
treatment can also be considered for patients who find
methadone and buprenorphine unacceptable but is generally
reserved for patients who are severely dependent and have been
refractory to all other treatments on many previous occasions.4 27
When heroin is not available, other medications, such as
hydromorphone, have been studied for such patients.28
Methadone and buprenorphine are now available in 73 countries,
and the evidence for effectiveness and cost effectiveness is far
stronger than for all other treatments for severe heroin
dependence.
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Box 1 Cost effectiveness of maintenance treatment versus no treatment*
• The incremental cost effectiveness ratio for methadone was £13 700 per QALY (quality adjusted life year) gained; the ratio for
buprenorphine was £26 400 per QALY gained.
• Methadone was more cost effective than buprenorphine in all scenarios considered because it is cheaper and yields marginally more
QALYs (0.067).
*From cost effectiveness analysis conducted by a NICE panel13
Box 2 Practical guidance for doctors
Start of treatment (first episode)
• Offer oral methadone or buprenorphine
• The choice of drug should be made jointly by the healthcare professional and the patient (and carer if the patient agrees) after
considering the options and taking into consideration the history of previous treatment and previous dose of methadone or buprenorphine
• Clarify that the aim of treatment is to achieve good adherence, stop injecting drug use, and stop use of non-prescribed drugs; where
this is not possible, the aim is to reach goals such as reduction in injecting and drug risk behaviour
• Before starting an opioid agonist, offer the patient electrocardiography if physical examination identifies a specific cardiovascular risk
or if the patient has a history of cardiovascular disease or a family history of long QT syndrome
• With methadone, begin treatment at the lower end of the licensed dose range and slowly titrate upwards. Doctors need to be aware
that methadone 30 mg can be a fatal dose in a non-tolerant individual. Once the patient has been inducted and stabilised, gradually
work up to a maximum dose of 60-120 mg over several weeks or months. Be aware that because of the long half life of methadone
the cumulative dosing will result in rising blood concentrations by the third day of treatment. When the patient reports high dependence
and high dose illicit heroin or methadone use, a clinician may titrate the dose upwards more quickly, but this is best done by a specialist
aware of the risk of dose accumulation and potential toxicity. Blood methadone concentrations continue to rise in the first week of
treatment, stabilising at 7-10 days. Evidence of intoxication or sedation in the early phase of treatment should result in a reduction in
dosage
• With buprenorphine, start with 4 mg and work rapidly up to 8 mg or 16 mg as clinically indicated and in discussion with the patient.
Again blood concentrations take 7 to 10 days to stabilise
• Throughout treatment, and especially during titration, monitor and record clinical response, adverse effects, physical health (including
changes in weight), and adherence. There is a risk of diversion of prescribed medication and there are dangers to individuals who
consume non-prescribed medication if they are not dependent. There are complex legal implications, moral responsibilities, and
potential harms around diversion. The nature of the doctor’s legal responsibilities differs in different jurisdictions. Doctors need to be
aware of the local regulations on prescribing controlled drugs. Treatment monitoring should aim to minimise diversion
Treatment of recurrence
• Be non-judgmental, as in any other condition, and encourage a fresh start and offer oral medication again. Base the choice of drug
on the criteria above as well as previous treatment response. Changing from buprenorphine to methadone or vice versa is a useful
way to have a fresh start and focus on options for treatment adherence, a treatment plan, and treatment goals
Maintenance treatment
• Listen clearly to and establish agreed treatment goals, both short and long term, and review progress on a quarterly basis. Review
long term goals annually
• Advise the patient of the high risk of relapse if he or she discontinues use in the next year
• When the response to agonist treatment is inadequate, review use of alcohol and psychostimulants and the adherence to and dose
of medication; consider other causes of non-response, such as comorbid mental health problems
Management of adverse effects
• If the patient reports unwanted effects such as excessive sweating, breakthrough withdrawal symptoms, abdominal discomfort, or
other somatic symptoms, consider either increasing the dose for withdrawal symptoms or switching to the alternative medication
(methadone or buprenorphine)
• Encourage patients to maintain a healthy diet and to exercise regularly to avoid excessive weight gain
• Encourage reduction or cessation of nicotine and cannabis; assess for the risk of blood borne virus and status (and inform the patient
about risks) and possible treatment need. Assess mood and risk of self harm when appropriate
Table











(intervention) v no treatment
(comparison)
High2.173.053 (1.75 to 5.35)†63/251 (25)173/254 (68)Retention12
Moderate1.590.323 (0.23 to 0.44)†110/126 (873)28/104 (27)Use of opiates12
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Box 3 Tips for patients*
• There are two main opioid-type agonist drugs that are effective and available: methadone and buprenorphine. Neither is perfect, but
both can help you stay away from heroin. Having a very clear focus on what you expect the drug to do will help. Both these drugs are
opioids and you will be dependent on them. Users’ views vary widely on the difficulty involved in coming off methadone, and some
users state that they would prefer to come off buprenorphine. It’s possible to work down to a low dose of methadone and switch to
buprenorphine, but many prefer to stick to the medication they are familiar with
• You need to be aware that, like heroin, these drugs when taken in larger doses can seriously suppress breathing and consciousness
and can result in overdose and death. Mixing these tablets with heroin and other opiates can also be dangerous and result in serious
consequences
• You will do much better if you are on a higher dose (methadone >80 mg/day; buprenorphine 12 mg/day); for a longer period (at least
18 months), think carefully about stopping treatment before doing so; plan your discharge from treatment and decrease the dose very
slowly (more than three months)
• If you are still using heroin, ask if your dose of your opioid can be increased
• This is a good time to try and sort out other problems in your life and engage in education, training, or to get work
• If you are provided with doses of methadone or buprenorphine, keep these in a child proof container in a safe place
• If you do inject drugs, make sure that you use a sterile needle and syringe every time
• Have a test for HIV and hepatitis C virus, and arrange vaccination for hepatitis A and B
• Try to stop smoking—if you need help to do this, phone a helpline, visit a website, or see a counsellor (phone Smokefree (0800 022
4 332) or go to http://smokefree.nhs.uk/; in Australia go to www.quitnow.gov.au/)
• Take care of your health, including dental health and gum disease, to ensure that dental disease that is caused by drug use is kept
to a minimum
• The length of treatment is variable. Some people who do very well on methadone and buprenorphine are advised to stay on it indefinitely;
others, after a period of stability, want to get off it. Some do so successfully, but many others find they have to restart the medication.
It is much better to restart the medication than to return to street heroin use and crime
• It is important that your GP or treatment specialist monitors your physical health as well as your mental health while you are receiving
treatment
• You can take methadone in liquid form usually once a day. Some people prefer to take it twice daily—this is usually more practical
once you are able to take medication home from the pharmacy
• Buprenorphine (and buprenorphine with naloxone) comes as a small tablet that is inserted under the tongue and dissolves; in some
countries it is available as a small film strip, which dissolves under the tongue more quickly than the tablet
• Alcohol and illicit drugs can interfere with the effects of the opioid drugs and can make you more likely to lose control of your substance
consumption and consume a range of other drugs
• It’s important that you make your treatment preference clear to your doctor and also that you make clear what you hope to get out of
the treatment and that you have a chance to review whether you are getting to where you want to get to and that other options for
change are considered if you feel that you have got stuck and stopped making progress











Low40.393 (0.12 to 1.25)†18/185 (10)5/178 (3)Criminal behaviour12
Moderate0.17 (0.05 to 0.63)†416/32454 (1.3)70/37516 (0.2)Overdose mortality3
Buprenorphine 16 mg (treatment)
v buprenorphine 1 mg
(comparison)11
High4.761.52 (1.23 to 1.88)†74/185 (40)110/181 (61)Retention





High9.620.85 (0.73 to 0.98)†340/537 (63)281/531 (53)Retention
−0.12 (−0.26 to 0.02)‡Percentage of urine samples positive
for morphine
−0.12 (−0.31 to 0.07)‡Self reported heroin use
*The GRADE (Grading of Recommendations Assessment, Development and Evaluation) system classifies strength of evidence as high when further research is
very unlikely to change confidence in the estimate of effect; moderate when further research is likely to have an important impact on confidence in the estimate of
effect, and may change the estimate; low when further research is very likely to have an important impact on confidence in the estimate of effect and is likely to
change the estimate; and very low when any estimate of effect is very uncertain.
†Relative risk.
‡Standardised mean difference.
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e2823 doi: 10.1136/bmj.e2823 (Published 15 May 2012) Page 5 of 5
PRACTICE
